Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic diseases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Lymphoma
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Follicular Lymphoma
• Hematological Diseases
• Lymphoblastic Lymphoma
• Lymphocytic Leukemia
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasm
• Non-hodgkin Lymphoma
• Plasma Cell Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: COMPLETED